These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2032473)

  • 1. Pharmacokinetics of cefodizime in normal individuals and in patients with renal failure.
    el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
    Chemotherapy; 1991; 37(2):77-85. PubMed ID: 2032473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of aztreonam in healthy volunteers and renal failure patients.
    el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
    J Chemother; 1989 Jun; 1(3):164-9. PubMed ID: 2795125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cefodizime in patients with various degrees of renal failure.
    Loffreda A; Lampa E; Lucarelli C; Amorena M; Contaldi C; Calderaro V; Rossi F
    Chemotherapy; 1999; 45(1):1-7. PubMed ID: 9876203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefodizime in patients with liver cirrhosis and ascites.
    el Touny M; el Guinaidy M; Abdel Bary M; Osman L; Sabbour MS
    Chemotherapy; 1992; 38(4):201-5. PubMed ID: 1473357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cefodizime administered intravenously as a single-dose (1.0 and 2.0 g) to healthy adult volunteers.
    Bryskier A; Procyk T; Tremblay D; Lenfant B; Fourtillan JB
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():65-70. PubMed ID: 2074253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.
    Lenfant B; Namour F; Logeais C; Coussediere D; Rivault O; Bryskier A; Surjus A
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2037-41. PubMed ID: 8540712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefotaxime after a single intravenous dose in patients with impaired renal function.
    Moukhtar I; Nawishy S; Sabbour M
    Chemioterapia; 1987 Feb; 6(1):38-40. PubMed ID: 3829135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics of cefodizime in critically ill elderly patients.
    Meyer B; Traunmueller F; Bojic A; Locker G; Schmid R; Winkler S; Thalhammer F
    Int J Antimicrob Agents; 2006 Apr; 27(4):335-8. PubMed ID: 16563704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
    Conte JE
    J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefodizime in elderly patients with moderate or severe renal impairment.
    Veyssier P; Devillers A; Domart Y; Fourtillan JB; Bryskier A; Procyk T
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():77-81. PubMed ID: 2074255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of cefodizime in patients undergoing hemodialysis].
    Itagaki N; Hasegawa H; Sakaguchi M; Oono T; Iwamoto I; Horiuchi H; Tsujino M; Takahashi K; Imada A; Horiuchi A
    Jpn J Antibiot; 1991 Dec; 44(12):1392-6. PubMed ID: 1798074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of cefodizime following intravenous and intramuscular administration of a single dose of 1.0 g.
    Bryskier A; Procyk T; Tremblay D; Lenfant B; Fourtillan JB
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():59-63. PubMed ID: 2074252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefodizime penetration into skin suction blister fluid following a single intravenous dose.
    Schäfer-Korting M; Korting HC; Maass L; Klesel N; Grigoleit HG; Mutschler E
    Eur J Clin Pharmacol; 1986; 30(3):295-8. PubMed ID: 3732363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefodizime during continuous ambulatory peritoneal dialysis.
    Mendes P; Lameire N; Rosenkranz B; Malerczyk V; Damm D
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():89-93. PubMed ID: 2074257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers.
    Korting HC; Schäfer-Korting M; Maass L; Klesel N; Mutschler E
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1822-5. PubMed ID: 3435129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure.
    Rodondi LC; Flaherty JF; Schoenfeld P; Barriere SL; Gambertoglio JG
    Clin Pharmacol Ther; 1989 May; 45(5):527-34. PubMed ID: 2721108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefodizime: a review of the data on file.
    Barré J
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():95-101. PubMed ID: 2074258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing time and sex-related differences in the pharmacokinetics of cefodizime and in the circadian cortisol rhythm.
    Jonkman JH; Reinberg A; Oosterhuis B; de Noord OE; Kerkhof FA; Motohashi Y; Levi F; Dammacco F; Carandente F
    Chronobiologia; 1988; 15(1-2):89-102. PubMed ID: 3416675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.